Skip to main content
. 2019 Nov 2;40(2):129–137. doi: 10.1007/s40261-019-00869-3

Fig. 3.

Fig. 3

a The cost-effectiveness acceptability curve. QALY quality-adjusted life-year. b Probability of cost-effectiveness of nivolumab versus docetaxel at different drug costs of nivolumab. Blue dotted lines represent the WTP threshold of US$63,564/QALY for affluent regions, orange dotted lines represent the WTP threshold of $28,899/QALY for general regions and $63,564/QALY. QALY quality-adjusted life years, WTP willingness-to-pay